as of 11-20-2026 3:59pm EST
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | FREDERICK |
| Market Cap: | 11.9M | IPO Year: | 2009 |
| Target Price: | N/A | AVG Volume (30 days): | 36.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | 13.64 |
| 52 Week Low/High: | $1.21 - $9.73 | Next Earning Date: | 11-12-2026 |
| Revenue: | $5,635,927 | Revenue Growth: | -27.17% |
| Revenue Growth (this year): | 111.8% | Revenue Growth (next year): | 52.23% |
| P/E Ratio: | -11.44 | Index: | N/A |
| Free Cash Flow: | -1201817.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SEC 8-K filings with transcript text
Nov 16, 2026 · 100% conf.
1D
-2.35%
$2.44
Act: -6.40%
5D
-6.94%
$2.33
20D
-7.60%
$2.31
2 tomz_ex991.htm
document.htm
TOMI Environmental Solutions, Inc. Reports Preliminary Third Quarter 2026 Financial Results
Company Delivers 24% Q3 Revenue Growth and Returns to Positive Operating Income
FREDERICK, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced preliminary financial results for the three and nine months ended September 30, 2026, and provided an update on strategic initiatives.
Select financial and operational achievements for the quarter are as follows:
● Q3 Revenue Increased 24% Year-Over-Year to $2.49 Million; Sequential Revenue Increased 11% Over Q2 2026.
● Achieved Positive Operating Income: Generated approximately $30,000 of operating income, representing the Company’s first positive quarterly operating result since the third quarter of 2024.
● Gross Profit Increased 19% to $1.47 Million; Gross Margin was 59.0%.
● Operating Expenses Decreased 7% Year-Over-Year and 12% Sequentially, reflecting continued expense discipline.
● Sales Backlog Reached Approximately $2.5 Million at Quarter-End and Approximately $2.8 Million Subsequently, supporting near-term revenue visibility.
● The company expects shareholders’ equity at September 30, 2026 to be in the range of $3 Million to $4 Million
The financial results in this press release are preliminary and unaudited. The Company and its independent registered public accounting firm have not yet completed their review of the accounting treatment for the Company’s convertible notes, including the conversion of $2.5 million of notes during the third quarter. Accordingly, this release does not include financial results that may be affected by that review, including any gain or loss associated with the conversion, net loss, net loss per share, and the related liability and stockholders’ equity balances. Based on information currently available, the Company does not expect the review to affect the revenue, gross profit, operating expense or income from operations figures presented in this release; however, all results remain subject to change until the Company files its Quarterly Report on Form 10-Q for the period ended September 30, 2026.
Executive Commentary
Dr. Halden Shane, CEO of TOMI Environmental Solutions, commented, “The third quarter represented an important inflection point for TOMI. Revenue increased 24% year-over-year and 11% sequentially, and we returned to positive operating income for the first time since the third quarter of 2024. This progress reflects stronger commercial execution, improved equipment sales and disciplined management of our operating cost base.”
“We also materially improved our capital structure during the quarter. The conversion of $2.5 million of convertible notes significantly reduced our debt obligations and expected annual cash interest commitment. Combined with an expanding backlog and commercial pipeline, we believe these improvements provide a stronger foundation as we work toward sustained profitability.”
“Operationally, momentum continued across mobile equipment, SteraMist applicators, BIT Solution consumables and support services. We also advanced our food safety, life sciences, defense and international regulatory initiatives, including the expanded AgriMist registration and independent Listeria biofilm data. We remain focused on converting our backlog and pipeline, increasing recurring revenue and delivering sustainable growth.”
1
Q3 2026 Highlights:
● Revenue Growth: Q3 2026 revenue was $2,492,801, a 24% increase from $2,011,556 in Q3 2025 and an 11% sequential increase from $2,246,909 in Q2 2026. Nine-month revenue increased 38% to $6,393,937 from $4,619,229.
● Positive Operating Income: Income from operations was $30,047, compared with an operating loss of ($321,415) in Q3 2025 and an operating loss of ($244,142) in Q2 2026.
● Gross Profit Growth: Gross profit increased 19% to $1,469,921 from $1,231,971 in Q3 2025. Gross margin was 59.0%, compared with 61.2% in the prior-year quarter.
● Disciplined Operating Expenses: Operating expenses decreased 7% year-over-year to $1,439,874 from $1,553,386 and decreased 12% sequentially from $1,629,448 in Q2 2026.
● Product and Domestic Revenue Growth: Product revenue increased 30% to approximately $2.08 million, while U.S. revenue increased 50% to approximately $1.92 million.
● Strong Product and Service Order Growth: Based on 2026 invoiced sales and open orders, iHP Support Services increased approximately 133%, Mobile Equipment increased approximately 106%, and CES/Enclosure sales increased approximately 259% compared with full-year 2025 levels. BIT Solution sales are on track to exceed 2025.
● Expanded Backlog and Pipeline: Sales backlog totaled approximately $2.5 million at September 30, 2026 and subseque
Aug 14, 2026 · 100% conf.
1D
-2.35%
$1.48
Act: +5.26%
5D
-6.91%
$1.42
20D
+0.65%
$1.53
Transcript text not available. View on SEC.gov →
Jul 29, 2026 · 100% conf.
1D
-2.35%
$1.48
Act: +5.26%
5D
-6.91%
$1.42
20D
+0.65%
$1.53
2 tomz_ex991.htm
tomz_ex991.htm
TOMI Environmental Solutions Reaffirms $12 Million Revenue Guidance for Fiscal 2026
and Confirms $35 Million Sales Pipeline with $8.6 Million in Advanced Stages
-Carbonium Merger Remains on Track
-European Regulatory Expansion and Partnership Growth
-Advancement of Biosafety Cabinet Standards
-Defense Sector Growth
Frederick, MD – July 29, 2026 — TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today reaffirmed its expectation to achieve revenue of at least $12 million in 2026. This is driven by strong first half trends, an increase of over 100% in sales and receipt of sales as compared to 2025, which has already exceeded the full 2025 year sales. Currently TOMI has secured over $6.2 million in booked orders and orders that are expected to be completed before year-end. Further, approximately $8.6 million of the Company’s current $35 million sales pipeline is in advanced stages.
The Company remains actively engaged with Carbonium Core following the signing of the definitive merger agreement, as we continue to work toward closing of the transaction in the second half of 2026. As previously announced, with the support of federal and state government, including the U.S. Department of Energy, Carbonium is conducting a pilot study to produce nuclear-grade graphite for 4th-generation nuclear reactors and plans to move to full-scale commercial production, and we look forward to the completion of the merger which we believe will significantly enhance the value and financial performance of our company.
In the second quarter of 2026, all four key metrics, BIT Solution sales, mobile equipment sales, single applicator sales and support services, showed both year-over-year and sequential growth. The increases in applicator sales and support services are primarily due to initiatives implemented in late 2024 and early 2025. The Company continues to pursue new growth markets, including robotaxis, biosecurity, drones and humanoid robotics.
International sales continue to be an expanding opportunity for the Company. TOMI’s innovative disinfection product is now approved for use in Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Spain, Great Britain, and Northern Ireland. We added in Switzerland through an amendment and anticipate receiving approvals in France, Switzerland, Ireland, Poland, Portugal, and Romania.
1
TOMI’s recent expansion of SteraMist registrations across the European Union has significantly strengthened the Company’s established European network. In Poland, our partnership with MedLine will soon be able to successfully market SteraMist under the DeconLine brand once mutual recognition is approved. Additionally, TOMI has deepened its commercial pipelines through dedicated partners in Germany, the United Kingdom, and the Netherlands, many of whom bring well-established commercial, healthcare and military networks. TOMI’s long-term partner in Israel is also actively deploying SteraMist technology to support regional containment efforts in response to an active Ebola outbreak.
In Puerto Rico, Integrated Services for Productivity and Validation (ISPV) is focused on driving adoption within the region’s strong life sciences and food manufacturing industries. In Argentina and surrounding markets, TOMI is collaborating with a new partner to pursue shared opportunities with major global accounts, including Pfizer, Fresenius Kabi, and Merck. This expansion complements the Company’s long-standing partnership with Bacteria Free in Chile, which is now extending its reach from life sciences into the food safety sector.
NSF International (“NSF”) an independent nonprofit organization of developed standards and certifies products for public health and safety is rewriting the rules on Biosafety Cabinet (BSC) decontamination. TOMI played a key role in advancing discussion at the June 2026 meeting. The industry is shifting away from listing legacy known methods and brands, such as paraformaldehyde, and moving toward strict, performance-based criteria focused on efficacy, validation, and material compatibility areas where SteraMist iHP technology excels.
Several high-quality opportunities within the pipeline underscore the strength of TOMI’s competitive positioning. These include a near-$1 million project initiated in Q2 involving the installation of four applicators per proprietary machine line at a major medical company, a large-scale opportunity now out for bid where our Canadian partners have secured access to supply eight Hybrid Systems, and a Custom Engineered System (“CES”) valued at approximately $1 million.
TOMI continues to expand its presence in the defense sector, having recently received approvals from defense contractors in Korea and defense agencies in Canada. While confidentiality agreements limit the disclosure of specific details, these relati
See how TOMZ stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "TOMZ TOMI Environmental Solutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.